JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
 QUICK SEARCH:   [advanced]


     


J Am Coll Cardiol, 2005; 45:1802-1806, doi:10.1016/j.jacc.2005.02.066
© 2005 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (12)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ingelsson, E.
Right arrow Articles by Lind, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ingelsson, E.
Right arrow Articles by Lind, L.

CLINICAL RESEARCH: HEART FAILURE

Inflammation, as Measured by the Erythrocyte Sedimentation Rate, Is an Independent Predictor for the Development of Heart Failure

Erik Ingelsson, MD*,*, Johan Ärnlöv, MD, PhD*, Johan Sundström, MD, PhD* and Lars Lind, MD, PhD{dagger},{ddagger}

* Public Health and Caring Sciences, Uppsala, Sweden
{dagger} Medical Sciences, Uppsala University, Uppsala, Sweden
{ddagger} Astra Zeneca R & D, Mölndal, Sweden

Manuscript received December 14, 2004; revised manuscript received February 16, 2005, accepted February 22, 2005.

* Reprint requests and correspondence: Dr. Erik Ingelsson, Department of Public Health and Caring Sciences, Section of Geriatrics, Uppsala University, Box 609, SE-75125 Uppsala, Sweden. (Email: erik.ingelsson{at}pubcare.uu.se).

OBJECTIVES: Our objective was to explore inflammation, measured as erythrocyte sedimentation rate (ESR), as a predictor for the development of heart failure (HF).

BACKGROUND: In recent years, evidence of the importance of inflammation in the pathophysiology of HF has emerged, and various inflammatory markers have been found to predict future HF. Erythrocyte sedimentation rate is an inexpensive and easily accessible marker of systemic inflammation, but to this date it is unknown whether ESR predicts subsequent HF.

METHODS: In a community-based prospective study of 2,314 middle-aged men free from HF, myocardial infarction, and valvular disease at baseline, ESR was analyzed in multivariable models together with established risk factors for HF (hypertension, diabetes, electrocardiographic left ventricular hypertrophy, smoking, obesity, and serum cholesterol) and hematocrit.

RESULTS: A total of 282 men developed HF during a median follow-up time of 30 years. In Cox proportional hazards analyses, ESR was an independent predictor of HF (hazard ratio 1.46 for highest quartile vs. the lowest, 95% confidence interval 1.04 to 2.06). This observation remained significant when also adjusting for interim myocardial infarction during follow-up.

CONCLUSIONS: Erythrocyte sedimentation rate was a significant predictor of HF, independent of established risk factors for HF, and interim myocardial infarction after three decades of follow-up in a population-based sample of middle-aged men. Our findings indicate that inflammation occurs early in the process leading to HF and that ESR could be used to evaluate this process.

Abbreviations and Acronyms
  BMI = body mass index
  CI = confidence interval
  ESR = erythrocyte sedimentation rate
  HF = heart failure
  HR = hazard ratio
  ICD = International Classification of Diseases
  IL = interleukin
  TNF = tumor necrosis factor
  ULSAM = Uppsala Longitudinal Study of Adult Men




This article has been cited by other articles:


Home page
Physiol. Rev.Home page
E. D. Abel, S. E. Litwin, and G. Sweeney
Cardiac Remodeling in Obesity
Physiol Rev, April 1, 2008; 88(2): 389 - 419.
[Abstract] [Full Text] [PDF]


Home page
Annals of Clinical & Laboratory ScienceHome page
T.-J. Wu, H.-Y. Ou, C.-W. Chou, S.-H. Hsiao, C.-Y. Lin, and P. C. Kao
Decrease in Inflammatory Cardiovascular Risk Markers in Hyperlipidemic Diabetic Patients Treated with Fenofibrate
Ann. Clin. Lab. Sci., January 1, 2007; 37(2): 158 - 166.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
E Ingelsson, J Arnlov, L Lind, and J Sundstrom
Metabolic syndrome and risk for heart failure in middle-aged men
Heart, October 1, 2006; 92(10): 1409 - 1413.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
E. Ingelsson, J. Arnlov, J. Sundstrom, B. Zethelius, B. Vessby, and L. Lind
Novel Metabolic Risk Factors for Heart Failure
J. Am. Coll. Cardiol., December 6, 2005; 46(11): 2054 - 2060.
[Abstract] [Full Text] [PDF]




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 2005 by the American College of Cardiology Foundation.